To test this, endometrial cancer cells were first treated with PI3K (200 μM of LY294002) and mTOR inhibitors (200 μM of Torin2) to reduce their respective downstream effector (pAKT Ser473 and p4EBP1Thr 37/46, respectively) kinase activity (Figure 4C) followed by treatment with sulforaphane. This evidence concerns the gene MTOR and endometrial cancer.